Definitive Contract W81XWH20C0066
Award Date
6/19/20
Potential Completion Date
9/29/23
Potential Value
$11M
Federal Agency
Medical Command
Awardee
Ophirex, Inc.
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
PSC Category
AN94 - R&D- Medical: Other (Engineering Development)
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Corte Madera, CA 94925, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
SBIR Program Phase III Action
Primary Consortia Member
Not listed
Similar Awards
Ophirex, Inc. has been awarded a firm fixed price definitive contract valued at $1,299,779 by the Department of the Army Medical Command. This contract is a Small Business Innovation Research Program Phase II award to further develop Ophirex's intravenous snakebite antidote varespladib. Specifically, the contract aims to improve recovery time following snakebite through metalloprotease inhibition. As a total small business set aside, this award will support Ophirex's continued medical research...
This is a $23,443,943.61 Firm Fixed Price definitive contract awarded by the Defense Health Agency (DHA) to Ophirex, Inc., a small business, to conduct follow-on Phase III research and development under the Small Business Innovation Research (SBIR) program. The contract is for the continued development of a broad-spectrum snakebite antidote, including an oral product and an intravenous clinical study. The contract has a total small business set-aside designation and is scheduled for completion...
The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense awarded a $16.5 million Other Transaction Agreement to Rigel Pharmaceuticals Inc. to support the development of a therapeutic to treat COVID-19. The prototype effort will take place in South San Francisco, California through May 2023. No set-aside designation was applied to this award made under the "COVID-19" PROTOTYPE DEVELOPMENT OF A THEREAPUTIC TO TREAT COVID-19 solicitation. As the...
This is a $9,407,618.00 firm fixed price definitive contract awarded by the Defense Health Agency to Ophirex, Inc., a small business, for the development of a broad-spectrum snakebite antidote. The contract is part of the U.S. Army Medical Research and Development Command's Small Business Innovation Research (SBIR) Phase III program, which provides for the continued research and development of technologies that have successfully completed Phases I and II. The contract aims to advance the...
This federal contract award, valued at $29,999,425.00, was granted by the Defense Health Agency (DHA) to Ophirex, Inc., a for-profit small business, for the "BROAD SPECTRUM SNAKEBITE ANTIDOTE: CONCLUSION OF ORAL PRODUCT DEVELOPMENT" project under the Small Business Innovation Research (SBIR) Program Phase III. The contract is an Other Transaction Agreement (OTA) and does not have a set-aside designation. Ophirex, Inc. will be responsible for completing the oral product development...
This is a $2,266,107.00 fixed-price cost-plus-fixed-fee contract awarded by the United States Special Operations Command (USSOCOM) to Surany Research And Development LLC, a small business contractor. The contract was awarded under the Small Business Innovation Research (SBIR) Phase II program and is focused on research and development related to the coronavirus (COVID-19) pandemic. The contract has a period of performance through March 31, 2022. Surany Research And Development LLC has previously...
This is a federal contract award to Regeneron Pharmaceuticals Inc., a for-profit manufacturer of pharmaceuticals and therapeutics. The $692,086,314.00 award was made by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services (HHS). The contract is for the development and production of "novel antibodies against influenza virus, emerging, re-emerging, and pre-emerging pathogens" under an Other...
This definitive contract awarded by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response to Orasure Technologies Inc. is valued at $710,310 to support the development of a rapid antigen test for COVID-19. The contract was awarded under Special Instructions 019 of the Easy Broad Agency Announcement BAA-20-100-SOL-0002 and will deliver research and development efforts towards a host-directed therapeutic to aid long-term outcomes from lung...
This is a $4,590,862.00 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Sorrento Therapeutics, Inc., a small disadvantaged business. The contract is for the "DEVELOPMENT OF IN VITRO FOR BIODEFENSE, ANTIMICROBIAL RESISTANT (AMR) INFECTIONS AND EMERGING INFECTIOUS DISEASES", which was a Broad Agency Announcement (BAA) research area. The contract has a period of performance through May 2, 2025...
This is a $526,793.52 Firm Fixed Price SBIR Phase II contract awarded by the Joint PEO Chemical and Biological Defense to Arisan Therapeutics Inc., a small disadvantaged business. The contract is for research and development services supporting the development of countermeasures against chemical and biological threats. This contract is a follow-on to previous SBIR Phase I and II awards to Arisan Therapeutics totaling over $790,000. The company has also received other federal research contracts...